An ISB-led study showed nuanced pregnancy outcomes for pregnant individuals with autoimmune disease. The findings reinforce that there isn’t a one-size-fits-all approach, and provides important new avenues for further investigation.
By using a computer model to understand the adaptions of Mycobacterium tuberculosis (Mtb), the pathogen that causes tuberculosis, researchers at ISB have identified a network within Mtb that allows it to tolerate and resist drug therapies. This work is published in Cell Reports.
Supplementing the standard of treatment for Alzheimer’s disease patients with personalized lifestyle coaching leads to less cognitive decline compared to standard of treatment alone, according to an ISB-led two-year study. The results were published in the Journal of Alzheimer’s Disease.
ISB researchers have constructed biological body mass index (BMI) measures that offer a more accurate representation of metabolic health and are more varied, informative and actionable than the traditional, long-used BMI equation. The work was published in the journal Nature Medicine.
In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.
ISB researchers have shown which blood metabolites are associated with the gut microbiome, genetics, or the interplay between both. Their findings, published in the journal Nature Metabolism, have promising implications for guiding targeted therapies designed to alter the composition of the blood metabolome to improve human health.
New ISB research shows that different patient responses to statins can be explained by the variation in the human microbiome. The findings were published in the journal Med, and suggest that microbiome monitoring could be used to help optimize personalized statin treatments.
A just-published study provides new information about which hospitalized COVID-19 patients are most likely to need mechanical ventilation or to die. The ISB-led work shows that vital signs and lab results at the time of hospital admission are the most accurate predictors of disease severity, more so than comorbidities and demographics.
Researchers have identified several factors that can be measured at the initial point of COVID-19 diagnosis that anticipate if a patient is likely to develop long COVID. They also found that mild cases of COVID-19, not just severe cases, are associated with long COVID. Their findings were published by the journal Cell.
An ISB-led study examined the electronic health records of more than 18,000 people with SARS-CoV-2 tests during pregnancy, and found that those who contracted COVID-19 while pregnant were more likely to have poor birth outcomes including preterm birth, small for gestational age, low birth weight, and stillbirth.
Tuberculosis (TB) is the world’s second leading infectious disease killer after COVID-19. Drug resistance to TB is a public health crisis. ISB researchers have developed algorithms to predict the efficacy of drugs in treating Mycobacterium tuberculosis (MTB), the causative agent for TB. These research findings were published in the journal Cell Reports Methods.
The strongest associations with weight loss success or failure – independent of BMI – are found in the genetic capacity of the gut microbiome. These new findings open the door to diagnostic tests that can identify people likely to lose weight with healthy lifestyle changes and those who might need more drastic interventions.
Researchers from Institute for Systems Biology (ISB), Fred Hutchinson Cancer Research Center and other organizations have uncovered underlying metabolic changes that regulate how immune cells react to COVID-19. These findings are associated with COVID-19 severity and may predict patient survival. The work was published in the journal Nature Biotechnology.
A recently developed method by the Wei Lab at Institute for Systems Biology (ISB) and University of California, Riverside provides new insights into cancer biology by allowing researchers to show how fatty acids are absorbed by single cells. This work was published in the Journal of the American Chemical Society.
To improve the efficacy of neoadjuvant immune checkpoint blockade against glioblastoma, researchers are looking for vulnerabilities in surgically removed tissues – a difficulty due to the vast differences within the tumor and between patients. To address this, ISB researchers and their collaborators developed a new way to study tumors.
Researchers from ISB’s Baliga Lab recently published a paper in the journal Frontiers in Marine Science, in which they identified a diatom-specific gene that may play a key role in predicting when diatoms might transition from a low/moderate to a high carbon dioxide environment.
ISB researchers and their collaborators looked at the electronic health records of nearly 630,000 patients who were tested for SARS-CoV-2, and found stark disparities in COVID-19 outcomes — odds of infection, hospitalization, and in-hospital mortality — between White and non-White minority racial and ethnic groups.
Despite the aggressive nature of Non-Small Cell Lung Cancer (NSCLC), circulating tumor cells that lead to metastases often go undetected in the blood. ISB researchers in Dr. Wei Wei’s lab and their collaborators have developed a novel method to better detect these circulating cells.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.